Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Phenylalanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | GSR | P00390 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.45 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylalanine SCHEMBL6130126 | 1.00 | SLC7A5 (0.56) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL22400727 | 1.00 | SLC7A5 (0.56) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL7330522 | 0.93 | SLC7A5 (0.54) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL15324236 | 0.91 | SLC7A5 (0.52) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL15324234 | 0.91 | SLC7A5 (0.52) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL20586939 | 0.89 | SLC7A5 (0.63) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL1921946 | 0.89 | SLC7A5 (0.63) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL1921945 | 0.89 | SLC7A5 (0.63) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL21314200 | 0.89 | SLC7A5 (0.71) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL20740839 | 0.89 | SLC7A5 (0.71) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10849840-B2 | Compositions and methods for stimulation MAGP-1 to improve the appearance of skin | NEW AVON LLC (US) | 2020-12-01 | — | — | US | claimed |
| EP-3272329-B1 | COMPOSITIONS AND METHODS FOR STIMULATION MAGP-1 TO IMPROVE THE APPEARANCE OF SKIN | AVON PROD INC (US) | 2020-09-16 | — | — | EP | claimed |
| US-10849840-B2 | Compositions and methods for stimulation MAGP-1 to improve the appearance of skin | NEW AVON LLC (US) | 2020-12-01 | — | — | US | disclosed |
| EP-3272329-B1 | COMPOSITIONS AND METHODS FOR STIMULATION MAGP-1 TO IMPROVE THE APPEARANCE OF SKIN | AVON PROD INC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20180271772-A1 | Compositions and Methods for Stimulation MAGP-1 to Improve the Appearance of Skin | AVON PRODUCTS, INC | 2018-09-27 | — | — | US | disclosed |
| US-9999587-B2 | Compositions and methods for stimulation MAGP-1 to improve the appearance of skin | AVON PRODUCTS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| EP-3272329-A2 | COMPOSITIONS AND METHODS FOR STIMULATION MAGP-1 TO IMPROVE THE APPEARANCE OF SKIN | Avon Products, Inc. (US) | 2018-01-24 | — | — | EP | disclosed |
| EP-2588593-B1 | COMPOSITIONS AND METHODS FOR STIMULATING MAGP-1 TO IMPROVE THE APPEARANCE OF SKIN | AVON PROD INC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20160008266-A1 | Compositions and Methods for Stimulation MAGP-1 to Improve the Appearance of Skin | CITIBANK, N.A., LONDON BRANCH | 2016-01-14 | — | — | US | disclosed |
| US-9132294-B2 | Compositions and methods for stimulation MAGP-1 to improve the appearance of skin | AVON PRODUCTS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2588593-A2 | COMPOSITIONS AND METHODS FOR STIMULATING MAGP-1 TO IMPROVE THE APPEARANCE OF SKIN | Avon Products, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012005876-A2 | COMPOSITIONS AND METHODS FOR STIMULATING MAGP-1 TO IMPROVE THE APPEARANCE OF SKIN | AVON PRODUCTS, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20120003332-A1 | Compositions and Methods for Stimulation MAGP-1 to Improve the Appearance of Skin | AVON PRODUCTS, INC. (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180271772-A1 | Compositions and Methods for Stimulation MAGP-1 to Improve the Appearance of Skin | MAG, MFAP1, CUTA | PTGS1 1429/4885SLC7A5 4765/4885ALPI 4488/4885 |
| US-20160008266-A1 | Compositions and Methods for Stimulation MAGP-1 to Improve the Appearance of Skin | MAG, MFAP1, CUTA | PTGS1 1429/4885SLC7A5 4765/4885ALPI 4488/4885 |
| US-10849840-B2 | Compositions and methods for stimulation MAGP-1 to improve the appearance of skin | MAG, MFAP1, CUTA | PTGS1 1429/4885SLC7A5 4765/4885ALPI 4488/4885 |
| US-20120003332-A1 | Compositions and Methods for Stimulation MAGP-1 to Improve the Appearance of Skin | MAG, MFAP1, CUTA | PTGS1 1429/4885SLC7A5 4765/4885ALPI 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.